tetano
Editor, Senior Moderator
Comput Biol Chem
. 2026 Feb 22:123:108969.
doi: 10.1016/j.compbiolchem.2026.108969. Online ahead of print.
Implications of cytokines in Memory B cell for risk stratification and therapeutic framework construction among Pediatric Influenza patents: insights from machine learning and multi-omics
Yunxia Zhang[SUP] 1 [/SUP], Qingkun Yuan[SUP] 2 [/SUP], Mengmeng Zhang[SUP] 3 [/SUP], Bing Han[SUP] 4 [/SUP], Jianjian Li[SUP] 5 [/SUP], Xuecong Ning[SUP] 6 [/SUP]
Affiliations
Objective: Cytokine storm and dysregulation of Memory B cell aggravate the symptoms and weaken the therapeutic effectiveness for Pediatric Influenza(PI) patents. Hence, deeper understanding of Integration cytokines and memory B cell can pave the way for the treatment of PI.
Methods: By integration of 2 peripheral blood bulk profiles of PI patients(GSE29366 and GSE42026) and integrative bioinformatic analysis, including CIBERSORT, WGCNA, Limma and 3 machine learning algorithms(RF, Lasso and SVM-RFE), we creatively identified Memory B cell-associated differentially expressed cytokines and hub cytokine for PI patients. Next, dignostic potential of hub cytokine was estimated in aforementioned 2 bulk profiles and independent validation peripheral blood bulk profiles of PI patients(GSE50628). Besides, consensus clustering empowered the molecular subgroups identification for PI patients based on Memory B cell-associated differentially expressed cytokines. Indeed, molecular and immune features were also estimated in peripheral blood bulk profile of PI patients (GSE42026) and peripheral blood single-cell transcriptomic profile of PI patients(GSE243629). Finally, therapeutic repurposing agent targeting hub cytokine for treatment of PI was assessed by DGIDB database and validated by molecular docking.
Results: MYD88 can be considered as up-regulated expression and Memory B cell distributed hub cytokine involved in PI pathogenesis, which illustrated favorable dignostic performance. Besides, 5 differentially expressed cytokines can divide PI patients into 2 consensus subgroups. Finally, Zanubrutinib can be considered as optimal therapeutic reproposing strategy targeting MYD88 for the treatment of PI.
Conclusion: Our study first revelated MYD88 can be considered as Memory B cell distribution cytokine serving for the diagnosis and treatment of PI patients.
Keywords: Cytokines; Machine learning; Memory B cells; Pediatric Influenza patents; Risk stratification; Therapeutic reproposing.
. 2026 Feb 22:123:108969.
doi: 10.1016/j.compbiolchem.2026.108969. Online ahead of print.
Implications of cytokines in Memory B cell for risk stratification and therapeutic framework construction among Pediatric Influenza patents: insights from machine learning and multi-omics
Yunxia Zhang[SUP] 1 [/SUP], Qingkun Yuan[SUP] 2 [/SUP], Mengmeng Zhang[SUP] 3 [/SUP], Bing Han[SUP] 4 [/SUP], Jianjian Li[SUP] 5 [/SUP], Xuecong Ning[SUP] 6 [/SUP]
Affiliations
- PMID: 41775124
- DOI: 10.1016/j.compbiolchem.2026.108969
Objective: Cytokine storm and dysregulation of Memory B cell aggravate the symptoms and weaken the therapeutic effectiveness for Pediatric Influenza(PI) patents. Hence, deeper understanding of Integration cytokines and memory B cell can pave the way for the treatment of PI.
Methods: By integration of 2 peripheral blood bulk profiles of PI patients(GSE29366 and GSE42026) and integrative bioinformatic analysis, including CIBERSORT, WGCNA, Limma and 3 machine learning algorithms(RF, Lasso and SVM-RFE), we creatively identified Memory B cell-associated differentially expressed cytokines and hub cytokine for PI patients. Next, dignostic potential of hub cytokine was estimated in aforementioned 2 bulk profiles and independent validation peripheral blood bulk profiles of PI patients(GSE50628). Besides, consensus clustering empowered the molecular subgroups identification for PI patients based on Memory B cell-associated differentially expressed cytokines. Indeed, molecular and immune features were also estimated in peripheral blood bulk profile of PI patients (GSE42026) and peripheral blood single-cell transcriptomic profile of PI patients(GSE243629). Finally, therapeutic repurposing agent targeting hub cytokine for treatment of PI was assessed by DGIDB database and validated by molecular docking.
Results: MYD88 can be considered as up-regulated expression and Memory B cell distributed hub cytokine involved in PI pathogenesis, which illustrated favorable dignostic performance. Besides, 5 differentially expressed cytokines can divide PI patients into 2 consensus subgroups. Finally, Zanubrutinib can be considered as optimal therapeutic reproposing strategy targeting MYD88 for the treatment of PI.
Conclusion: Our study first revelated MYD88 can be considered as Memory B cell distribution cytokine serving for the diagnosis and treatment of PI patients.
Keywords: Cytokines; Machine learning; Memory B cells; Pediatric Influenza patents; Risk stratification; Therapeutic reproposing.